Capstone Therapeutics (NASDAQ: CAPS) reported Q2 EPS of ($0.13), $0.16 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $12.85 million versus the consensus estimate of $15.05 million.

For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.